KC
Therapeutic Areas
Mayne Pharma Group Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Nextstellis (drospirenone/estetrol) | Oral Contraception / Hormone Therapy | Approved |
| Lidocaine Topical System 1.8% | Postherpetic Neuralgia (PHN) | Approved |
| Fabior (tazarotene) Foam | Acne Vulgaris | Approved |
| Sorilux (calcipotriene) Foam | Plaque Psoriasis | Approved |
| Doryx (doxycycline hyclate) MPC | Severe Acne | Approved |
| Pipeline of Complex Generics | Various | Development |
| Pipeline of 505(b)(2) Products | Various (Women's Health, Dermatology) | Pre-clinical to Phase 3 |
Leadership Team at Mayne Pharma Group
SR
Scott Richards
Non-Executive Chairman
SL
Shaun Larkin
Managing Director & Chief Executive Officer
DC
David Cowley
Chief Financial Officer
DM
Dr. Michael Thick
Chief Medical Officer
M(
Michael (Mick) O'Brien
Chief Commercial Officer, US Generics
DJ
Dr. James (Jim) Hall
President, Mayne Pharma International & President, Mayne Pharma USA (Branded)
BM
Brent Matthews
Chief Operating Officer
DM
Dr. Michelle Miller
Chief Scientific Officer (Development)
P(
Phillipa (Pippa) Leary
Non-Executive Director
J(
John (Rob) Kelly
Non-Executive Director